Skip to main content

Advertisement

SpringerLink
Log in

Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly

  • Geriatrics (S Katz, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Among inflammatory bowel disease (IBD) patients, 4–12 % is diagnosed after the age of 60. Both the rates of elderly and IBD are increasing worldwide. In older patients, the diagnosis of Crohn’s disease (CD) and ulcerative colitis (UC) is made more difficult due to polypharmacy and multimorbidity along with disease processes that mimic IBD. The clinical presentation in older-onset IBD differs from younger patients, and there is minimal disease progression over time. The management of the older IBD patient involves a combination of medical and surgical strategies. Few treatment efficacy studies exist in elderly IBD as most authors have focused on the adverse events related to therapy. A vast number of incident CD and UC cases in elderly have been treated with 5-aminosalicylic acid agents and do not require the use of immune modifying agents or biologics. Many other older IBD patients are prescribed long-term corticosteroids despite guidelines recommending more effective and safer maintenance therapy regimens. Serious infections, malignancy, and drug interactions are the most concerning complications of medical therapy. There are particularly important health care maintenance issues in older IBD patients including vaccinations, colorectal cancer screening, and bone loss prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Banks BM, Klayman MI. Idiopathic ulcerative colitis beginning after the age of fifty. N Engl J Med. 1953;249:91–6.

    Article  CAS  PubMed  Google Scholar 

  2. Law DH, Steinberg H, Sleisenger MH. Ulcerative colitis with onset after the age fifty. Gastroenterology. 1961;41:457–64.

    Article  CAS  PubMed  Google Scholar 

  3. Nugent FW. Regional ileitis with onset in patients over fifty years of age. Gastroenterology. 1958;35:418–9.

    Article  CAS  PubMed  Google Scholar 

  4. del Val JH. Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17:2734–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27:617–24.

    Article  PubMed  Google Scholar 

  6. Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterol Hepatol. 2008;4:337–47.

    Google Scholar 

  7. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97.

    Article  PubMed  Google Scholar 

  8. Ruel J, Ruane D, Mehandru S, et al. IBD across the age spectrum: is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11:88–98.

    Article  PubMed  Google Scholar 

  9. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32. Population-based French study using EPIMAD registry between 1988–2006 that leads to many of the conclusions about the natural history and approach to treatment in older-onset IBD.

    Article  PubMed  Google Scholar 

  10. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977–2008. J Crohns Colitis. 2011;5:5–13. Population-based Hungarian study between 1977–2008 that leads to many of the conclusions about the natural history and approach to treatment in older-onset IBD.

    Article  PubMed  Google Scholar 

  11. In: A profile of older Americans. 2011. Administration of aging. http://aoa.gov/Aging_Statistics/Profile/2011/4.aspx. Accessed 25 Jan 2015.

  12. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.

    Article  PubMed  Google Scholar 

  13. Nilsen T, Sundström J, Lind L, et al. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem. 2014;47:1065–8.

    Article  CAS  PubMed  Google Scholar 

  14. Stoller MA, Stoller EP. Perceived income adequacy among elderly retirees. J Appl Gerontol. 2003;22:230–51.

    Article  Google Scholar 

  15. Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606–13.

    Article  PubMed  Google Scholar 

  16. Collins CE, Ayturk MD, Flahive JM, et al. Epidemiology and outcomes of community-acquired clostridium difficile infections in medicare beneficiaries. J Am Coll Surg. 2014;218:1141–7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014;70:1159–72.

    Article  CAS  PubMed  Google Scholar 

  18. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65.

    Article  PubMed  Google Scholar 

  19. Parian AM, Ha CY. Su1130 severe polypharmacy and major medication interactions are associated with increasing age and comorbidity among inflammatory bowel disease patients. Gastroenterology. 2013;144:S-406.

    Article  Google Scholar 

  20. Singh S, Kullo IJ, Pardi DS, et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:26–35.

    Article  PubMed  Google Scholar 

  21. Long MD, Kappelman MD, Martin CF, et al. Risk factors for depression in the elderly inflammatory bowel disease population. J Crohns Colitis. 2014;8:113–9.

    Article  PubMed  Google Scholar 

  22. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793–6.

    Article  CAS  PubMed  Google Scholar 

  23. Amati L, Passeri M, Selicato F, et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol Immunotoxicol. 2006;28:665–81.

    Article  CAS  PubMed  Google Scholar 

  24. Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259–63.

    Article  CAS  PubMed  Google Scholar 

  25. Greenwald DA, Brandt LJ. Inflammatory bowel disease after age 60. Curr Treat Options Gastroenterol. 2003;6:213–25.

    Article  PubMed  Google Scholar 

  26. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5. Multicenter retrospective Italian study from 2000–2009 evaluating the safety of infliximab and adalimumab in patients >65 years old is responsible for several of the conclusions drawn regarding efficacy and safety profile of biologic use in elderly.

    Article  CAS  PubMed  Google Scholar 

  27. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–63.

    Article  PubMed  Google Scholar 

  28. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54:960–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–33.

    Article  CAS  PubMed  Google Scholar 

  31. Hawthorne AB, Stenson R, Gillespie D, et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis. 2012;18:1885–93.

    Article  PubMed  Google Scholar 

  32. Kane SV, Sumner M, Solomon D, et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56:3463–70.

    Article  CAS  PubMed  Google Scholar 

  33. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617–29.

    Article  CAS  PubMed  Google Scholar 

  34. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 2010:Cd008870.

  35. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–83. The American College of Gastroenterology guidelines for the management of adult CD.

    Article  PubMed  Google Scholar 

  36. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218–26.

    Article  CAS  PubMed  Google Scholar 

  37. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–73.

    Article  CAS  PubMed  Google Scholar 

  38. Van Staa TP, Travis S, Leufkens HG, et al. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126:1733–9.

    Article  PubMed  CAS  Google Scholar 

  39. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13:629–38.

    Article  PubMed  Google Scholar 

  40. de Graaf P, de Boer NK, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol. 2010;160:1083–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Cino M, Greenberg GR. Bone mineral density in Crohn’s disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002;97:915–21.

    Article  CAS  PubMed  Google Scholar 

  42. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.

    Article  CAS  PubMed  Google Scholar 

  43. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.

    Article  PubMed  Google Scholar 

  44. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501–23. The American College of Gastroenterology guidelines for the management of adult UC.

    Article  PubMed  Google Scholar 

  45. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309–15. Along with [26], this retrospective single-center study evaluated the efficacy of ant-TNF agents in the elderly.

    Article  PubMed  Google Scholar 

  46. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

    Article  CAS  PubMed  Google Scholar 

  47. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

    Article  CAS  PubMed  Google Scholar 

  48. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.

    Article  PubMed  Google Scholar 

  49. Toruner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.

    Article  PubMed  Google Scholar 

  50. Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1795–802.

    Article  CAS  PubMed  Google Scholar 

  51. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22. Large, prospective, observational registry comparing risk factors for serious infection and mortality among CD patients taking or not taking infliximab.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2013;63:1416–23.

    Article  PubMed  Google Scholar 

  53. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145:1007–15.

    Article  CAS  PubMed  Google Scholar 

  54. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT Registry. Am J Gastroenterol. 2014;109:212–23. Large, prospective, observational registry comparing risk factors for various malignancies among CD patients taking or not taking infliximab.

    Article  CAS  PubMed  Google Scholar 

  55. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909–15.

    Article  CAS  PubMed  Google Scholar 

  56. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–51.

    Article  CAS  PubMed  Google Scholar 

  57. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–8.

    Article  CAS  PubMed  Google Scholar 

  60. Syrigos KN, Tzannou I, Katirtzoglou N, et al. Skin cancer in the elderly. In Vivo. 2005;19:643–52.

    PubMed  Google Scholar 

  61. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9.

    Article  PubMed  Google Scholar 

  62. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.

    Article  PubMed  Google Scholar 

  63. Peyrin-Biroulet L, Chevaux JB, Bouvier AM, et al. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. Am J Gastroenterol. 2012;107:1443–4.

    Article  CAS  PubMed  Google Scholar 

  64. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363–9.

    Article  PubMed  Google Scholar 

  65. Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207–19.

    Article  CAS  PubMed  Google Scholar 

  66. Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–21.

    Article  CAS  PubMed  Google Scholar 

  67. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.

    Article  CAS  PubMed  Google Scholar 

  68. Kim M, Dam A, Green J. Common GI drug interactions in the elderly. Curr Treat Options Gastroenterol. 2014;12:292–309.

    Article  PubMed  Google Scholar 

  69. Kaplan GG, Hubbard J, Panaccione R, et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64.

    Article  PubMed  Google Scholar 

  70. Fries W, Viola A, Mannetti N, et al. P303 ulcerative colitis (UC) in the elderly–moderate at onset but then a milder course? An IG-IBD study. J Crohns Colitis. 2014;8:S190–1.

    Article  Google Scholar 

  71. Viola A, Cantoro L, Monterubbianesi R, et al. P542 Crohn’s disease (CD) in the elderly – an IG-IBD study. J Crohns Colitis. 2014;8:S293–4.

    Article  Google Scholar 

  72. Almogy G, Sachar DB, Bodian CA, et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg. 2001;136:1396–400.

    Article  CAS  PubMed  Google Scholar 

  73. Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43.

    Article  PubMed  Google Scholar 

  74. Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? Arch Surg. 2005;140:534–9.

    Article  PubMed  Google Scholar 

  75. Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238:221–8.

    PubMed  PubMed Central  Google Scholar 

  76. Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003;186:514–8.

    Article  PubMed  Google Scholar 

  77. Lakatos PL, Vegh Z, Lovasz BD, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis. 2013;19:1010–7.

    Article  PubMed  Google Scholar 

  78. Triantafillidis JK, Mantzaris G, Karagiannis J, et al. Similar response to adalimumab in patients with active Crohn’s disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi. 2010;114:85–90.

    CAS  PubMed  Google Scholar 

  79. Meyer AM, Ramzan NN, Heigh RI, et al. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006;51:168–72.

    Article  CAS  PubMed  Google Scholar 

  80. Miao XP, Li JS, Ouyang Q, et al. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Cochrane Database Syst Rev 2014;10:Cd007744.

  81. Martin TD, Chan SS, Hart AR. Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci 2014

  82. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.

    Article  PubMed  Google Scholar 

  83. Kugelberg E. T cell memory: the effect of ageing on CD8+ T cells. Nat Rev Immunol. 2014;14:3–3.

    Google Scholar 

  84. Horton HA, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med. 2014;30:17–28.

    Article  PubMed  Google Scholar 

  85. Cossio-Gil Y, Martinez-Gomez X, Campins-Marti M, et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2015;30:92–8.

    Article  CAS  PubMed  Google Scholar 

  86. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009;15:1410–6.

    Article  PubMed  Google Scholar 

  87. Mattar MC, Lough D, Pishvaian MJ, et al. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011;4:53–61.

    PubMed  PubMed Central  Google Scholar 

  88. Crispin A, Birkner B, Munte A, et al. Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies. Endoscopy. 2009;41:1018–25.

    Article  CAS  PubMed  Google Scholar 

  89. Gatto NM, Frucht H, Sundararajan V, et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95:230–6.

    Article  PubMed  Google Scholar 

  90. Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol. 2010;8:166–73.

    Article  PubMed  Google Scholar 

  91. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795–9.

    Article  CAS  PubMed  Google Scholar 

  92. Etzel JP, Larson MF, Anawalt BD, et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011;17:2122–9.

    Article  PubMed  Google Scholar 

  93. Lau AN, Adachi JD. Bone aging. In: Geriatric rheumatology. Springer; 2011. p. 11–16.

  94. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.

    Article  PubMed  Google Scholar 

  95. Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Sasha Taleban declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. The University of Arizona Medical Center, 1501 N. Campbell Ave, Tucson, AZ, 85724, USA

    Sasha Taleban MD

Authors
  1. Sasha Taleban MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sasha Taleban MD.

Additional information

This article is part of the Topical Collection on Geriatrics

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taleban, S. Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastro 13, 275–286 (2015). https://doi.org/10.1007/s11938-015-0059-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-015-0059-6

Keywords

Search

Navigation